Skip to main content
news
A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. REUTERS/Julie Steenhuysen

Cleary Gottlieb Steen & Hamilton has advised Japanese pharmaceutical giant Takeda on its planned acquisition of U.S.-based Nimbus Therapeutics' experimental psoriasis drug, with Goodwin Procter acting for the seller.

The deal value is expected to be up to $6 billion, reported Reuters. It added that the drug, codenamed "NDI-034858", has shown statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year.

The Goodwin team was led by partners Bill Collins, Sarah Solomon and Yasin Akbari in Boston, and Erini Svokos in New York.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.